PT3565844T - Métodos de tratamento de cancro com anticorpos anti-pd-1 - Google Patents

Métodos de tratamento de cancro com anticorpos anti-pd-1

Info

Publication number
PT3565844T
PT3565844T PT187041017T PT18704101T PT3565844T PT 3565844 T PT3565844 T PT 3565844T PT 187041017 T PT187041017 T PT 187041017T PT 18704101 T PT18704101 T PT 18704101T PT 3565844 T PT3565844 T PT 3565844T
Authority
PT
Portugal
Prior art keywords
antibodies
methods
treating cancer
cancer
treating
Prior art date
Application number
PT187041017T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of PT3565844T publication Critical patent/PT3565844T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT187041017T 2017-01-09 2018-01-09 Métodos de tratamento de cancro com anticorpos anti-pd-1 PT3565844T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762444336P 2017-01-09 2017-01-09
US201762477423P 2017-03-27 2017-03-27
US201762491220P 2017-04-27 2017-04-27
US201762556386P 2017-09-09 2017-09-09

Publications (1)

Publication Number Publication Date
PT3565844T true PT3565844T (pt) 2023-05-02

Family

ID=61188903

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187041017T PT3565844T (pt) 2017-01-09 2018-01-09 Métodos de tratamento de cancro com anticorpos anti-pd-1

Country Status (21)

Country Link
US (2) US11407830B2 (OSRAM)
EP (2) EP3565844B8 (OSRAM)
JP (2) JP7110206B6 (OSRAM)
KR (1) KR102606252B1 (OSRAM)
CN (1) CN110382545A (OSRAM)
AU (2) AU2018206481B2 (OSRAM)
BR (1) BR112019014187A2 (OSRAM)
CA (1) CA3049440A1 (OSRAM)
DK (1) DK3565844T5 (OSRAM)
ES (1) ES2945745T3 (OSRAM)
FI (1) FI3565844T3 (OSRAM)
HU (1) HUE061842T2 (OSRAM)
IL (1) IL267804B2 (OSRAM)
MA (1) MA47208A (OSRAM)
MX (1) MX2019008207A (OSRAM)
PL (1) PL3565844T3 (OSRAM)
PT (1) PT3565844T (OSRAM)
SG (2) SG11201906192SA (OSRAM)
TW (1) TWI767976B (OSRAM)
WO (1) WO2018129559A1 (OSRAM)
ZA (1) ZA201904316B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3534950A4 (en) * 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
US12358984B2 (en) 2018-02-13 2025-07-15 Merck Sharp & Dohme Llc Methods for treating cancer with anti-PD-1 antibodies
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
EP3860988A1 (en) 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase
ES2967517T3 (es) 2018-10-03 2024-04-30 Tesaro Inc Sales de niraparib
US20200199567A1 (en) * 2018-12-20 2020-06-25 Medimmune, Llc Methods for selection and expansion of t cells expressing pd-1
JP7710997B2 (ja) * 2019-05-31 2025-07-22 エーエルエックス オンコロジー インコーポレイテッド 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法
CN115298218A (zh) * 2019-12-18 2022-11-04 特沙诺有限公司 生物药物组合物和相关方法
US20230094843A1 (en) * 2019-12-31 2023-03-30 Fukang (Shanghai) Health Technology Co., Ltd Pharmaceutical combination for treating tumors and application thereof
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20230038044A1 (en) * 2020-02-18 2023-02-09 Innobation Bio Co., Ltd. Companion diagnosis biomarker composition and companion diagnosis kit containing same
CA3178156A1 (en) * 2020-04-07 2021-10-14 Metanoi Therapeutics, Inc. Ethanolamine formulation for treating epithelial ovarian carcinoma
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
IL298946A (en) * 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2022025482A1 (ko) * 2020-07-29 2022-02-03 재단법인 아산사회복지재단 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물
WO2022090529A1 (en) * 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
CN115607664A (zh) * 2021-07-15 2023-01-17 嘉和生物药业有限公司 抗pd-1抗体在治疗宫颈癌中的应用
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
WO2023153763A1 (ko) * 2022-02-08 2023-08-17 고려대학교 산학협력단 C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations
TW202509063A (zh) * 2023-08-21 2025-03-01 瑞士商百濟神州瑞士有限責任公司 用抗lag3、抗pd-1和化學療法治療食管癌

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7414171B2 (en) 2000-11-15 2008-08-19 Ono Pharmaceutical Co., Ltd. PD-1-lacking mouse and use thereof
EP1383912A4 (en) 2001-04-02 2007-11-28 Wyeth Corp PD-1, B7-4 RECEPTOR, AND ITS USES
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
EP1997887B1 (en) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
DK2074145T5 (en) 2006-10-02 2017-10-16 Ac Immune Sa HUMANIZED ANTIBODY AGAINST AMYLOID BETA
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
PL2805945T3 (pl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
PT2131860E (pt) 2007-03-20 2014-03-04 Lilly Co Eli Anticorpos antiesclerostina
US7867491B2 (en) 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2650308A3 (en) 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
PH12012501761A1 (en) * 2010-03-17 2012-11-12 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
US20130035472A1 (en) 2010-03-17 2013-02-07 Anaptysbio, Inc. Method of producing transcripts using cryptic splice sites
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
US20130217656A1 (en) 2010-08-12 2013-08-22 Beth Israel Deaconess Medical Center Inc Methods and compositions for diagnosing and treating lupus
US20130310266A1 (en) 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
TWI496886B (zh) 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
EP2756094B1 (en) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
WO2013177102A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
WO2013174997A1 (en) 2012-05-25 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170088626A1 (en) 2014-03-05 2017-03-30 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PL3177644T3 (pl) 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
RS61470B1 (sr) 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
WO2016112870A1 (en) 2015-01-16 2016-07-21 Tse-Wen Chang Molecular constructs with targeting and effector elements
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
DK3283107T3 (da) * 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
EP3534950A4 (en) * 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
EA201990741A1 (ru) 2016-11-29 2019-11-29 Антитела, направленные против белка-1 запрограммированной смерти (pd-1)
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
CA3049536A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法

Also Published As

Publication number Publication date
CA3049440A1 (en) 2018-07-12
IL267804B2 (en) 2024-09-01
SG10201913075RA (en) 2020-02-27
PL3565844T3 (pl) 2023-06-12
EP3565844B8 (en) 2023-04-12
KR102606252B1 (ko) 2023-11-23
KR20190114996A (ko) 2019-10-10
US11407830B2 (en) 2022-08-09
FI3565844T3 (fi) 2023-05-09
EP3565844A1 (en) 2019-11-13
ES2945745T3 (es) 2023-07-06
MX2019008207A (es) 2019-12-11
JP7110206B2 (ja) 2022-08-01
US12415855B2 (en) 2025-09-16
JP2020504141A (ja) 2020-02-06
DK3565844T3 (da) 2023-05-01
BR112019014187A2 (pt) 2020-02-11
WO2018129559A1 (en) 2018-07-12
EP4219563A2 (en) 2023-08-02
IL267804B1 (en) 2024-05-01
US20230111418A1 (en) 2023-04-13
DK3565844T5 (da) 2024-09-02
TW201831200A (zh) 2018-09-01
ZA201904316B (en) 2022-12-21
CN110382545A (zh) 2019-10-25
EP4219563A3 (en) 2023-10-04
MA47208A (fr) 2019-11-13
AU2018206481A1 (en) 2019-07-25
EP3565844B1 (en) 2023-03-01
US20200239574A1 (en) 2020-07-30
AU2025200639A1 (en) 2025-02-27
SG11201906192SA (en) 2019-08-27
JP7110206B6 (ja) 2022-08-25
JP2022082809A (ja) 2022-06-02
AU2018206481B2 (en) 2025-02-27
IL267804A (en) 2019-09-26
TWI767976B (zh) 2022-06-21
HUE061842T2 (hu) 2023-08-28

Similar Documents

Publication Publication Date Title
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL275663A (en) Cancer treatment methods
IL308805B2 (en) Anti-PD-1 antibodies for the treatment of lung cancer
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL263925A (en) Methods of treating ovarian cancer
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
ZA202005223B (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
PL3455259T3 (pl) Skojarzenie przeciwciał anty-pd-1 i radioterapii w celu leczenia nowotworu
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL262342A (en) Cancer treatment methods
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
SG11202005163PA (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
HK40016654A (en) Methods of treating cancer with anti-tim-3 antibodies
HK40053388B (en) Claudin6 antibodies and methods of treating cancer
HK40030315A (zh) 抗-fam19a5抗体用於治疗癌症的用途